Lab
Arbor Vita Corporation
Arbor Vita Corporation was paid $6.30M by Medicaid between Jan 2022 and Dec 2024, across 5 billing codes. Its largest line is 87636, Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B — 78% of everything it billed.
33Billing provider infoARBOR VITA CORPORATION
FREMONT, CA 94538
FREMONT, CA 94538
33aNPI1821057407assigned 03/21/2006
33bProvider typeClinical Medical Laboratory
28Total paid$6.30M
24GClaims57,311
24DCodes billed5
24AFirst – last monthJan 2022 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#97 of 561
Median peer was paid$222K
This provider vs. median28×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 2,187 | $138K | |
| 2023 | 20,645 | $2.15M | |
| 2024incomplete | 34,479 | $4.01M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 78% | 41,127 | 7,267 | $4.93M |
| 86769 | 20% | 10,952 | 5,674 | $1.28M | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.2% | 4,092 | 2,710 | $75K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 167 | 147 | $10K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 973 | 635 | $7K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLU, PETER (CEO)